ClinConnect ClinConnect Logo
Search / Trial NCT01183533

Safety of Intravenous Thrombolysis for Wake-up Stroke

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Aug 16, 2010

Trial Information

Current as of May 23, 2025

Completed

Keywords

Wake Up Stroke Ischemic Stroke Ischemic Stroke Patients Who Wake Up With Their Symptoms

ClinConnect Summary

This is an open label, multi-center, safety study of acute treatment with IV alteplase in ischemic stroke patients who wake-up with their symptoms. The primary outcome of this study is the frequency of symptomatic hemorrhagic transformation evident within 24 hours of treatment with IV t-PA. Clinical improvement defined as a decrease in the National Institutes of Health Stroke Scale (NIHSS) score at 24 hours, 3 days and 90 days and modified Rankin Scale (mRS) score at 3 and 90 days. For patients that have computed tomographic angiogram (CTA) and computed tomographic perfusion (CTP), the inci...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Suspected acute ischemic stroke that occurred during sleep or patients who wake up with focal neurological symptoms. This includes all patients who were last known to be neurologically normal the night before,but then found upon awakening with stroke deficits. It will be considered that the last known onset time is the time when the patient was last known to be well.
  • 18 to 80 years old
  • NIHSS (National Institutes of Health Stroke Scale) ≤25
  • Blood Pressure ≤185 mmHg systolic \& ≤110 mmHg diastolic at the time of enrollment.
  • Treatment of higher systolic BP is permitted, prior to enrollment
  • IV t-PA must be given within 3 hours of awakening from sleep
  • Female patients of child-bearing potential must have a negative pregnancy test prior to enrollment
  • Exclusion Criteria:
  • CT Exclusion Criteria: Hypodensity \>1/3 middle cerebral artery (MCA) territory on non-contrast cranial CT scan or evidence of intracranial or subarachnoid hemorrhage
  • Prior ischemic stroke within 3 months of the presenting event
  • History of intracranial hemorrhage
  • Known secured or unsecured cerebral aneurysm or vascular malformation
  • Inability to control systolic BP \> 185 mmHg or diastolic BP \> 110 mmHg with IV anti-hypertensive medications
  • Known coagulopathy or evidence of active bleeding
  • Surgical procedures, biopsy, subclavian venous or arterial puncture, trauma within 14 days of the event
  • Gastrointestinal or genitourinary bleeding within 14 days of the event
  • Treated with IV heparin within the previous 24 hours \& an abnormal (partial thromboplastin time) PTT
  • Oral anticoagulants \& an (international normalized ratio) INR \>1.7
  • Platelet count \<100,000
  • Venous glucose either \<50 or \>450
  • Any patient who qualifies for this protocol should not be treated with (intra-arterial therapy) IAT If the treating physician believes a patient should undergo IAT, those patients should be identified a priori and not enrolled into this protocol

About The University Of Texas Health Science Center, Houston

The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.

Locations

Englewood, Colorado, United States

Birmingham, Alabama, United States

Houston, Texas, United States

Patients applied

0 patients applied

Trial Officials

Sean I Savitz, MD

Principal Investigator

UT-Houston Health Science Center

Andrew D Barreto, MD

Principal Investigator

Study Co-PI

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials